Stay updated with breaking news from Nasdaq Grph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have earned an average rating of “Hold” from the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a hold recommendation to the company. The average 1-year price target among analysts […]
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at Cantor Fitzgerald decreased their FY2023 earnings per share (EPS) estimates for Graphite Bio in a research report issued on Tuesday, May 16th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings per share of ($0.99) for the year, down from […]
Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have been given an average rating of “Hold” by the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year price target among […]
Lodestar Private Asset Management LLC purchased a new stake in shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 14,199 shares of the company’s stock, valued at approximately $47,000. A number of other hedge funds and other institutional investors have also bought and sold […]
Graphite Bio (NASDAQ:GRPH – Get Rating) and Compugen (NASDAQ:CGEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Volatility and Risk Graphite Bio has a beta of 0.01, […]